Results 231 to 240 of about 23,474 (264)

Talimogene laherparepvec (T-VEC) as a treatment for melanoma: A systematic review

Journal of Oncology Pharmacy Practice
Background and aims Melanoma now presents an average risk of 1 in 50 in the Western world. Talimogene laherparepvec (T-VEC), an FDAapproved oncolytic virus derived from Herpes Simplex Virus type 1 (HSV-1), has proven effective in reducing morbidity and mortality from melanoma but causes adverse effects like chills, fever ...
Sai Santhosha Mrudula Alla, Yogesh Tekuru, Moraboina Sai Lokesh, Deekshitha Alla, Patel Tvisha, Soujanya Tirupati, Aradhya Singh, Yeshala Tejaswini, Mariya Mahmood, Nanki Pratap Siingh, Bodipudi Vineetha   +10 more
openaire   +2 more sources

Talimogene Laherparepvec (T-VEC): Expanding Horizons in Oncolytic Viral Therapy Across Multiple Cancer Types

Anti-Cancer Agents in Medicinal Chemistry
Abstract: Talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic viral therapy, has transformed cancer immunotherapy since its 2015 approval for unresectable melanoma. Engineered from Herpes Simplex Virus type 1 (HSV-1) with deletions in ICP34.5 and ICP47 genes and GM-CSF insertion, T-VEC selectively
Run-Bin Tan, Yeannie Hui-Yeng Yap
openaire   +2 more sources

Fortgeschrittenes Melanom: zusätzliche Gabe von T-VEC ohne Nutzen

hautnah dermatologie, 2023
openaire   +1 more source

Exanthem nach einmaliger Injektion von T‐VEC

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019
Daniel, Wagenknecht, Johannes, Kohlmann, Arno, Rütten, Mirjana, Ziemer   +3 more
openaire   +2 more sources

Rash after a single injection of T‐VEC

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2019
Daniel Wagenknecht, Johannes Kohlmann, Arno Rütten, Mirjana Ziemer   +3 more
openaire   +1 more source

Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa

New England Journal of Medicine, 2022
Matt Peter Marinkovich, suma krishnan
exaly  

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature Medicine, 2023
Hatem H Soliman, Deanna Hogue, Mooney BP
exaly  

ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC

Annals of Surgical Oncology, 2022
Emma H. A. Stahlie, Alexander C. J. van Akkooi   +1 more
openaire   +2 more sources

Revisit the VEC criterion in high entropy alloys (HEAs) with high-throughput ab initio calculations: A case study with Al-Co-Cr-Fe-Ni system

Journal of Alloys and Compounds, 2022
Songge Yang, Yu Zhong
exaly  

SynSig2Vec: Forgery-Free Learning of Dynamic Signature Representations by Sigma Lognormal-Based Synthesis and 1D CNN

IEEE Transactions on Pattern Analysis and Machine Intelligence, 2022
Songxuan Lai, Lianwen Jin, Zhe Li
exaly